



PriorityOne AC Aspiration Catheter

COMPANY	Terumo Interventional Systems
PHONE	(800) 862-4143
WEB	www.terumo.com/products/aspiration/priorityone.aspx
KEY FEATURES • Rounded, short-tip design preserves crossability • Fully braided, stainless steel body • Guidewire stylet minimizes kinking • Excellent pushability and trackability for thrombus removal from coronary or peripheral arteries	

Terumo Interventional Systems (Somerset, NJ) recently launched the PriorityOne AC aspiration catheter. The PriorityOne AC's rounded, short-tip design preserves crossability and reduces vessel wall adhesion. The catheter's design makes it possible to apply the additional force needed in challenging anatomy to guide the catheter to the blockage and restore blood flow to the occluded artery.

The fully braided, stainless steel body and guidewire-style stylet minimizes kinking while maintaining pushability and trackability for thrombus removal from the coronary or peripheral arteries.

"Aspiration, or thrombectomy, catheters are excellent tools for helping to clear blocked arteries, but kinking can be a problem as the device is advanced," said Michael Martinelli, MD, Chief of Cardiology at St. Peter's Hospital in Albany, NY. "The PriorityOne AC offers impressive features, such as full-length stainless steel braiding and preloaded guidewire type of stylet, which increase deliverability and kink resistance ensuring optimal crossability even in difficult scenarios." ■



Xience Xpedition

COMPANY	Abbott
PHONE	+32 2 7141411
WEB	www.abbottvascular.com
KEY FEATURES • New stent delivery system designed to optimize acute performance • Supported by clinical evidence of Xience—more than 45,000 patients across 100+ trials • Approval includes expanded CE Mark indications for complex disease and for 3-month DAPT • Offered in a broad size matrix, including a unique 3.25-mm diameter	

The Xience Xpedition everolimus-eluting coronary stent system (Abbott Vascular, Santa Clara, CA) is now available in Europe and other CE Mark countries for the treatment of coronary artery disease. Xience Xpedition features a new stent delivery system designed to optimize acute performance, particularly in challenging coronary anatomies. Xience Xpedition is available with a broad range of indications, including use with a minimum duration of 3 months of dual-antiplatelet therapy (DAPT), the shortest duration of DAPT required for any major drug-eluting stent in Europe.

The Xience family of stents is supported by robust clinical evidence with data from more than 45,000 patients across more than 100 studies and long-term outcomes out to 5 years. Xience Xpedition is available in one of the broadest size matrices on the European market, including a unique 3.25-mm diameter and lengths up to 38 mm.

"The extraordinary deliverability of the new Xience Xpedition drug-eluting stent system allows physicians to treat particularly complex coronary disease with great ease and confidence," said Evald H. Christiansen, MD, PhD, an interventional cardiologist with the Department of Cardiology, Aarhus University Hospital in Skejby, Denmark. ■

